secwatch.observer — SEC 8-K summary
======================================

Issuer:     Summit Therapeutics Inc. (SMMT)
CIK:        0001599298
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0001599298-24-000113
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Summit Therapeutics Q2 net loss $60.4M; ivonescimab achieves first Phase III win over Keytruda
--------------------------------------------------------------------------------

- GAAP net loss $60.4M ($0.09/sh) vs $14.7M ($0.02) in Q2 2023; non-GAAP loss $34.3M.
- Cash $325.8M (up from $186.2M) after $200M June equity offering; runway into Q4 2025.
- HARMONi-2: ivonescimab monotherapy beat pembrolizumab in 1L NSCLC, first drug to do so in Phase III.
- HARMONi-A: ivonescimab+chemo reduced progression/death by 54% (HR 0.46) in EGFR-mutated NSCLC post-TKI.
- Expanded license to Latin America, Middle East, Africa; five-year strategic collaboration with MD Anderson.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1599298/000159929824000113/0001599298-24-000113-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1599298/000159929824000113/smmt-20240806.htm
  HTML page:      https://secwatch.observer/filing/0001599298-24-000113

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer